PainReform Ltd. (PRFX)
2.27
-0.18 (-7.35%)
At close: Mar 28, 2025, 3:59 PM
2.30
1.40%
After-hours: Mar 28, 2025, 06:55 PM EDT
Company Description
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel.
It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.
The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair.
PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
PainReform Ltd.
| Country | IL |
| IPO Date | Sep 1, 2020 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Dr. Ehud Geller Ph.D. |
Contact Details
Address: 65 Yigal Alon Street Tel Aviv, IL | |
| Website | https://www.painreform.com |
Stock Details
| Ticker Symbol | PRFX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001801834 |
| CUSIP Number | M77798102 |
| ISIN Number | IL0011651580 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ehud Geller Ph.D. | Interim Chief Executive Officer & Executive Chairman |
| Dr. Sigal Aviel | Chief Operating Officer |
| Eyal Broder | Interim Chief Financial Officer |
| Prof. Eli Hazum Ph.D. | Chief Technology Officer & Director |
| Dr. Stephen A. Cooper D.M.D Ph.D. | Executive Vice President of Development |
| Rita Keynan | Vice President of Pharmaceutical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 05, 2025 | 6-K | Filing |
| Feb 27, 2025 | 6-K | Filing |
| Feb 26, 2025 | 6-K | Filing |
| Feb 18, 2025 | 6-K | Filing |
| Jan 02, 2025 | 424B5 | Filing |
| Jan 02, 2025 | 6-K | Filing |
| Dec 27, 2024 | 6-K | Filing |
| Dec 12, 2024 | 424B3 | Filing |
| Dec 06, 2024 | F-3 | Filing |
| Dec 04, 2024 | 6-K | Filing |